52 results about "Nontuberculous mycobacteria" patented technology

The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. Tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria. Four recently characterized proteins with this diagnostic potential were selected. Peptides from these proteins were tested one by one with peripheral blood mononuclear cells from microscopy or culture confirmed TB patients as well as from healthy BCG vaccinated controls. Some combinations of peptides showed a sensitivity level comparable to the level seen with the two wellknown M. tuberculosisspecific proteins ESAT 6 and CFP 10. An epitope combination with these peptides combined with ESAT 6 and CFP 10 gave a sensitivity of 93%, representing a raise in sensitivity of about 26-33% compared to using ESAT6 or CFP 10 alone. The results from a panel of TB patients, using a collection of the new specific epitopes clearly demonstrates, that addition of other specific epitopes to the already known specific antigens, increases the sensitivity of a diagnostic assay based on cell mediated immune response.

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

The invention belongs to the field of a detection reagent, and relates to a detection and identification kit for MTBC (mycobacterium tuberculosis complex) and an identification method of the MTBC. According to the method, fluorescence probes and amplification primers for detecting the MTBC are designed through sequence alignment, mycobacterium and the MTBC specific SNP (single nucleotide polymorphism) loci on an rrs gene are detected based on a real-time fluorescent quantitative PCR (polymerase chain reaction) platform and with an asymmetric PCR amplification technology and a probe melting curve analysis technology, so that mycobacteria are identified, and the MTBC and NTM (nontuberculosis mycobacteria) are further identified. The method has the characteristics of convenience in operation, short detection time and high specificity and sensitivity.

Provided herein are methods for treating a pulmonary infection in a patient in need thereof for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.

The currently used method for immunological diagnosis of tuberculosis infection, the tuberculin skin test, is problematic for a number of reasons; it has low specificity in BCG vaccinated individuals, a high interobserver variance and requires skill to be read and interpreted. Furthermore it requires an extra visit to the clinic to have the test read. Both people vaccinated with BCG and those exposed to non-tuberculosis mycobacteria give a positive skin test result similar to that seen in a TB infected individual. This also applies for purified protein derivative (PPD) when used in a blood cell based test. The present invention discloses the development of an immunological TB diagnostic tool based on a combination of epitopes from proteins encoded by regions of the M. tuberculosis (M. tub.) genome, that are not present in the BCG vaccine strain or in the most common non-tuberculosis mycobacteria.

The invention provides a test paper of nucleic acid amplification product for detecting tubercle mycobacterium (TB) and Nontuberculous mycobacteria (NTM), comprising (a) (avidin-gold release region) and (b) test belt. The invention further provides a method of detecting TB and NTM, comprising (a) amplifying the sample DNA of primer having mark; (b) mixing the amplified DNA product by electrophoretic buffer; (c) dipping the test paper in the mixture; and (d) flowing the mixture in the reaction area of the paper.

The invention discloses a fluorescence quantitative nucleic acid detection technique for differentiating and identifying Mycobacterium tuberculosis and nontuberculous mycobacteria in one step based on the features of dual-channel fluorescence quantitative detection, which has a short detection time, provides reliable detection results and achieves the quantitative detection. The invention adopts the technical scheme as follows: a kit for identifying Mycobacterium tuberculosis and nontuberculous mycobacteria is provided, which comprises primers for PCR (polymerase chain reaction) amplification of strains to be detected and probes for fluorescence quantitative detection. According to the invention, according to the difference in gene sequence of different types of mycobacteria, the fluorescence probes are designed to differentiate Mycobacterium tuberculosis from nontuberculous mycobacteria; and the differentiation and identification is performed at the levels of gene sequence and molecular structure of bacterial strains, so as to ensue more accurate and more reliable classification. The invention solves the problem that in the conventional identification method, the differentiation based on the growth forms of bacterial strains needs a long period of time up to 4 to 6 weeks.

The invention discloses a molecular beacon probe for quickly detecting non-Mycobacterium tuberculosis. The invention is characterized in that the base sequence of the molecular beacon probe is BeaconNTM: 5'-CY3-(b)CATTG( / b)TACGCCCATAATTCGGAC(b)CAATG( / b)-BHQ1-3', wherein the 5' terminal of the probe is marked with Cy3, the 3' terminal is marked with BHQ1, the fluorophore excitation wavelength is 552nm, and the detection wavelength is 570nm. The molecular beacon probe has the advantages of high signal intensity and high specificity, and can effectively and quickly detect non-Mycobacterium tuberculosis. The invention also discloses a kit and detection method for quickly detecting non-Mycobacterium tuberculosis.

The present invention provides: a primer set and / or a probe for detecting Mycobacterium tubericulosis and nontuberculous mycobacteria specific for a Mycobacterium tubericulosis-specific IS6110 gene or 16S rRNA gene and a nontuberculous mycobacteria-specific 16S rRNA gene; a kit for detecting Mycobacterium tubericulosis and nontuberculous mycobacteria, containing the same; and a method for detecting Mycobacterium tubericulosis and nontuberculous mycobacteria through dual real-time polymerase chain reaction by using the same. The present invention can provide a clinical diagnosis means capable of more effectively detecting and analyzing Mycobacterium tubericulosis and / or nontuberculous mycobacteria at the same time.

The invention relates to a double-marking probe detecting and melting curve analyzing method used for identifying mycobacterium strains and a kit using the method to identify various mycobacterium strains at the same time. The kit provided by the invention comprises a primer capable of designing mycobacterium 16S rRNA, a double-marking oligonucleotide probe capable of identifying mycobacterium strains, and a thermostable DNA polymerase without 5' nuclease activity. The detecting method and the kit, which are provided by the invention, can detect and / or identify 24 kinds of common mycobacteria. The method and the kit can judge the results according to melting peaks of different Tm values produced by the sequence hybridization of the probe and the different strains, meanwhile rapidly and accurately detect the mycobacteria, and identify the mycobacteria, non-mycobacteria, mycobacterium tuberculosis compounding groups and nontuberculosis mycobacteria, and the result of identifying the mycobacteria can be reported after 3-4 hours, thus the method and the kid can assist the clinical diagnosis, and guide efficient clinical chemotherapy at the early stage.

Provided is a method for detecting mycobacterium tuberculosis and nontuberculous mycobacteria through a duplex polymerase chain reaction, the method using a kit for detecting mycobacterium tuberculosis and nontuberculous mycobacteria, the kit including a primer set for detecting mycobacterium tuberculosis and nontuberculosis mycobacteria specific to the mycobacterium tuberculosis-specific IS6110 gene or 16s rRNA gene and the nontuberculous mycobacteria-specific 16s rRNA gene. The present invention provides a clinical diagnosis means for more efficiently detecting mycobacterium tuberculosis and / or nontuberculous mycobacteria simultaneously using inexpensive general PCR equipment.

The present invention provides: primers for detecting mycobacterium tuberculosis and nontuberculous mycobacteria, the primers being specific respectively to a mycobacterium tuberculosis-specific IS6110 gene and a nontuberculous mycobacteria-specific 16S rRNA; a mycobacterium tuberculosis and nontuberculous mycobacteria detection kit including the primers; and a method for detecting mycobacterium tuberculosis and nontuberculous mycobacteria by means of a duplex real-time polymerase chain reaction using the primers and by means of a melting curve analysis. The present invention can provide a clinical diagnostic means that can quickly detect mycobacterium tuberculosis and / or nontuberculous mycobacteria simultaneously and more effectively, at a lower cost, since the invention does not use a sequence-specific probe.